The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials
Authors' conclusion
Semaglutide 2.4 mg was associated with improvement in health utility scores compared with placebo, reaching statistical significance in STEP 1, 2 and 4.
Study context
- Population
- Individuals with body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with ≥1 comorbidity (STEP 1, 3, 4), or BMI ≥27 kg/m² and T2D (STEP 2); lifestyle intervention plus intensive behavioural therapy in STEP 34 RCTs
- Comparison
- Semaglutide 2.4 mg vs placebo
- Primary endpoint
- Health utility: SF-36v2 converted to SF-6Dv2 utility scores or mapped onto EQ-5D-3L utility index (UK weights)
- Follow-up
- Week 68
Methodological detailsphase 3a, 68-week, double-blind
- Phase 3a
- 68-week
- Double-blind
Primary result
As reported in the abstract
Health utility scores
- Semaglutide 2.4 mg: minor health utility score improvements from baseline (all trials); placebo scores typically decreased
- Semaglutide 2.4 mg vs Placebo: P ≤ 0.001
- Semaglutide 2.4 mg vs Placebo: not significant
- Semaglutide 2.4 mg vs Placebo: P < 0.001 for all
- Semaglutide 2.4 mg vs Placebo: not significant
Original publication
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials. Diabetes Obes Metab. Published 8 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →